Compare Intuitive Surgical, Inc. (ISRG) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuitive Surgical, Inc. vs Tango Therapeutics Inc. — how do they compare? Intuitive Surgical, Inc. trades at $420.57 (market cap $149.10B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Intuitive Surgical, Inc. is far larger — about 39.8× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Intuitive Surgical, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Intuitive Surgical, Inc. for 84 Days and Tango Therapeutics Inc. for 0 Days on average.
| ISRG | TNGX | |
|---|---|---|
Market Cap | $149.10B | $3.75B |
Volume | 1,732,647 | 9,619,106 |
Sector | Health | Health |
52-Week High | $592.85 | $32.90 |
52-Week Low | $332.02 | $7.50 |
Typical Hold Time | 84 Days | 0 Days |
Enterprise Value | $143.89B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuitive Surgical (ISRG) trades at $420.24, down 1.73% on the day, but maintains strong fundamentals with consistent earnings beats and robust revenue growth. The company reported $10.06B in 2025 revenue with 28.45% net margins, while technical indicators show a bullish trend with support at $414. Recent news highlights international expansion in India and Japan to offset China weakness.
ISRG presents a compelling investment case with 70% analyst buy ratings and a $480.78 price target offering 14% upside. Key risks include competitive pressures in robotic surgery and procedure growth concerns, but the company's market leadership and recurring revenue model support long-term growth prospects.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
